Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Anyone adding RVNC at these levels ? Wonder when the catalyst is to get some investor attention.
Meanwhile CFO hiring could come anytime. Hoping they get a good candidate.
They have big wig marketing folks from AGN joined and seem to plan for a significant lead time (almost 1 year now) to do all market analysis and pre-commercialization activities.
I would have preferred they do not take any chance if they have any iota of doubt & ending up signing co-partner on weakness later.
Does anyone subscribe to thesis that if RVNC decides to market/commercialize RT002 on their own, they may not be successful ?
My take is RT002’s excellent product profile should help to sell itself anyway.
Thanks. May be the logistics is more complicated than I thought when you have 10b5-1 plan. Hoping they get a great CFO candidate soon to ease some investor anxiety :)
Jokes aside, just curious why insiders not buying even with a token purchase ? I don’t think with ER period behind, quiet period is a problem.
Agree. I also have large position in ADMA. Apart of near term catalysts, this is a growth story stock with potential to be acquired down the road. Biologics companies tend to be great complementary to IO pharma cos.
RVNC - may be I missed but on the CC did they share any information of filling CFO vacancy ?
It would be nice if they can get another high profiler like they did in other cases.
Is he bullish on RVNC by chance ? :)
Yep. The problem was compounded by the fact his ‘recommendations’ were mostly small caps that could move significantly. So it’s easy always to get the same price like he did on both way in & out. I later realized his followers were basically selling to each other after the king has left the castle lol
Anyone adding here with this ridiculous sell off ? Oversold for sure
Not surprised. He was front running mostly anyway.
RVNC - added today. Slide on weak volume and on no news. I believe no ATM is active. Just macros ?
Wonder which other companies are in this space ? ARYC QTNT ?
FMI was in 20’s in 2016 and I remember how expectations were tracked (# of tests etc.) on this board with bull thesis tapering away eventually.
IOVA I believe whose TIL technology was used by Dr Rosenberg. Use of TIL not being new in preclinical setting, these case studies results are stunning nevertheless. Great news for unfortunate patients.
Any reason for big jump today other than Roth upgrade ?
Thanks. I am curious how far EOLS toxin could be categorized as ‘generic’ version of Botox, the fact they are not differentiating.
From commercial labeling point of view, I understand no way they can claim as such.
Added to my LT position here. Good opportunity IMO
Dew, how do you see the competition landscape now that EOLS is gearing up albeit CRL on CMC issues. T.I.A
Thanks, keeping close watch in upcoming cross over data but I am holding my shares as well. XENE
Thanks ! Ohad Hammer’s CNS blog on XENE among others is very informative.
Anyone following XENE ?
Their POC data for XEN1101 from P1a trial apparently was quite good though N is small. Most importantly no AE comp to ezogabine (serious retinal & skin pigmentation)
Data from P1b cross over is due this summer, I believe
Good point as I didn’t consider the 3.8% net investment income tax for high returns.
However you slice it, hard to escape paying the tax for sure !
Exactly :). That’s the reason I have my ENTA in Roth and bought bunch of RVNC in Roth as well. Plan to swap ENTA for RVNC soon.
When I switched jobs in 2010 I got lucky with ‘no penalty’ rule on IRA to Roth IRA conversion and on hindsight glad I converted fully and invested in stocks.
<off topic>
don’t understand the topic of CG taxes as it often comes up. 20% on long term gains has to be paid no matter whether after 1 year or 15 year.
However better alternative that I have followed last few years has been to use my Roth IRA to grow my portfolio. I certainly don’t need money now but knowing the ‘growth’ will be 100% tax free for ever is big bonus.
Could it be that ex-US partnership if it comes soon could allow Revance to launch RT002 lot earlier than in US?
Dying to know what brand name they eventually come up with :)
Which down are you referring to ? Just to be sure. :)
Dew, can’t help asking..knowing what you know (execution, product potential, market size, IP rights etc.) do you see similar trajectory for RVNC in couple of years ?
Question may be hypothetical but nice to dream for sure :) T.I.A
Thanks for chiming in. I remember collapse of Cempra on their AB Soli that had very good efficacy but showed ALT elevations albeit transient as Co claimed. FDA shot down just on that AE alone.
Hard to compete against MDGL’s drug that actually lowers the ALT. I will pass
VKTX - does anyone have an opinion on their VK2809’s safety and ALT enzyme elevations ? Seen few reports that such elevations was not properly characterized. T.I.A
Agree with Dew. Happy patients are key to recurring revenue for providers and in fact #1 reason why they can’t afford to go wrong administering even the existing Botox. So when it comes to RT002, providers will be clamoring to tout such a long acting option.
Agree. I listened to the interview as well. Sharp guy and he is careful not pumping the pipeline until P3 is out but at the same time he is confident on P2 data for efficacy & safety superiority.
APD371 probable success not built into valuation.
Any reason why AVXS is around $209+ when ‘all cash’ deal is at $218 ? Pricing any slight risk of deal not going thru ?
Good DD feeling already like a millionaire owning RVNC 15k shares :)
Nice summary with plenty of valid points to make bull thesis for ARNA.
One correction. JPM is in whole different league than lot smaller & run of a mill JMP securities.
Waiting to see JPM PT hike soon now that they had CC today.
Not necessarily as any pre launch campaign is ok as long they clearest disclose they are waiting on approval.
The key aspect to such an heads start is they see it as a big cosmetic campaign which requires building growing excitement into launch date among users both current & potential who may be lured due to long acting effect of RT002.
Certainly getting early buy-in from providers could be part of agenda so that co is well prepared when it comes to pricing (hopefully with premium).
If today’s solid bounce were to keep its trend, those put options won’t work well for the buyer.
Looks like JPM conf call today with ARNA was well received.
Looks like ARNA sell-off is over done. Almost to the levels prior to data release. I added more today.
Upcoming APF 371 data for pain is next catalyst I think.
Thanks for sharing. Apparently such world class hires esp ex-AGN will add more wrinkles to AGN’s Botox future.
Revance, well done :)
Would be interesting to get any info tomorrow as to whether they are looking for partnerships for P3 trials or plan to go alone now that they have huge cash coffer.